Registration & Refreshments

Chair's Closing Remarks / End of Day One

Lunch

Networking Drinks Reception

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

Morning Refreshments / One-to-One Meetings / Poster Presentations

PANEL DISCUSSION:

Natural Antibodies: beyond bispecifics

SVY JOHNSON

VP, Antibody Engineering 
Consultant, Macrogenics

RAKESH DIXIT

VP, Research 
& Development
Global Head Biologics Safety, 
Medimmune

JENNY KARLSSON

Head of TCR Biochemistry, 
Bayer
Targeted Thorium Conjugates:
Novel first in class targeted alpha therapy

SOPHIA KARAGIANNIS

Reader in Translational Cancer 
Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London

TRIPLE NEGATIVE BREAST CANCER

targeted therapy with anti-Folate Receptor alpha antibodies

FLAME CONVERSATIONS:

FLAME CONVERSATIONS:

FLAME CONVERSATIONS:

FLAME CONVERSATIONS:

FLAME CONVERSATIONS:

FLAME CONVERSATIONS:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

Afternoon Refreshments / One-to-One Meetings / Poster Presentations

PANEL DISCUSSION:

Making a Difference in Pediatric Leukemias & Orphan Blood Disorders

CHRISTIAN BREUNIS

Group Leader Biomarker 
& Cell Biology, Heidelberg Pharma

POLARIA as a putative predictive biomarker for treatment with 
Amanitin-based ADCs

JOHAN NILVERBRANT

Researcher, School of Engineering 
Sciences in Chemistry, 
Biotechnology and Health, KTH
Antibody libraries based on an autonomous human variable domain

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

SOLUTION PROVIDER PRESENTATION:

18:20: Chair’s Closing Remarks / End of Day One

18:20: Networking Drinks Reception
The Research & Technology Series: Immuno-oncology is a multi-event forum for exploring the latest developments in key areas of immuno-oncology. It will bring together 350 industry and academic leaders at the cutting edge of research and provides you with an opportunity to make connections with industry experts, researchers, investors and businesses in your field.

100 individual presentations will be given across the five meetings. Talks will look to cover the potential of predictive biomarkers such as the tumour mutation burden to enhance personalised care, and new biomarker and antigen discovery, as well as the development of novel large molecule immunotherapies including new antibody formats and T cell therapeutics.

Your delegate pass gives you access to all these meetings.

- **Adaptive Cell Transfer Congress**
- **Novel Antibody Therapeutics Congress**
- **Flow Cytometry Congress**
- **TMB & Neoantigen Congress**
- **Liquid Biopsies Congress**